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Table 1. Hemodynamics at Rest and During Steady State Submaximal Exercise of Patients With Isolated Aortic Regurgitation and
Healthy Volunteers
Healthy Volunteers (n [ 12)
Patients With Isolated Aortic
Regurgitation (n [ 12)
Age, yrs 25 (19–38) 22 (10–40)
Weight, kg 70 (53–95) 64 (29–83)
Rest
Steady State Submaximal
Exercise p Value Rest
Steady State Submaximal
Exercise p Value
Heart rate, beats/min 64 (57–91) 90 (71–115) 0.002 72 (57–87) 90 (76–135) 0.002
Systolic blood pressure, mm Hg 110 (102–126) 126 (104–143) 0.002 111 (97–134) 121 (99–160) 0.026
Diastolic blood pressure, mm Hg 60 (51–81) 73 (43–94) 0.003 53 (42–65) 64 (56–90) 0.005
LVEDV, ml/m2 73 (59–99) 74 (53–100) 118 (52–193) 102 (54–173) 0.004
LVESV, ml/m2 20 (15–34) 19 (13–32) 38 (18–66) 27 (14–51) 0.009
LVEF, % 73 (61–80) 72 (62–80) 68 (58–73) 71 (65–83) 0.021
Cardiac index, l/min/m2 3.6 (2.9–5.0) 4.6 (3.7–6.6) 0.002 3.0 (1.8–6.0) 4.8 (2.6–7.6) 0.004
Net antegrade ﬂow, ml 103 (86–128) 95 (83–138) 112 (51–239) 103 (49–256)
Aortic regurgitation, % d d 35 (9–64) 16 (7–42) 0.003
Values are median (range).
LVEDV ¼ left ventricular end diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end systolic volume.
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315To investigate the change of AR and LV volumes, all healthy
volunteers and patients with isolated AR were studied by a standard
cardiac 1.5-T CMR scanner during rest and steady-state submaxi-
mal exercise. LV end-diastolic and end-systolic volumes and aortic
forward and backward ﬂow were measured in a routine fashion, as
previously described (5) (Table 1).
In patients with isolated AR, the amount of AR decreased clearly
and uniformly during exercise. This ﬁnding may impact clinical
decision making, because according to American College of Car-
diology/American Heart Association guidelines, exercise testing is
used as a selection criterion to provoke symptoms during exercise.
However, as shown in our study, AR decreases during exercise.
Additionally, AR at rest correlated with increase of cardiac index
during submaximal exercise (R2 ¼ 0.64; p ¼ 0.001).
We believe that submaximal exercise is an important, but underused,
tool to study hemodynamic changes if myocardial perfusion is not the
objective, because most hemodynamic changes occur at lower levels of
exercise (4). Furthermore, submaximal exercise offers longer observation
time and can be tolerated by ill patients.
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Transcatheter Solution for
Pure Aortic Insufﬁciency
Surgically untreated aortic insufﬁciency (AI) is associated with a 10-
year mortality rate of 34% and the development of signiﬁcant heart
failure in 50% of patients (1). Approximately 10% of AI patients are
not offered surgery, mainly due to age or signiﬁcant comorbidities
(2). Transcatheter aortic valve implantation is an established and
growing technology for calciﬁed aortic stenosis. Calcium on the
aortic valve leaﬂets and annulus is used to anchor the transcatheter
heart valve (THV). However, pure AI lacks calciﬁcation with which
to anchor the THV with ongoing dilation of the aortic annulus,
promoting valve malposition or embolization (Figs. 1A to 1C).
With no dedicated system on the horizon, off-label THVs have
been implanted in selected high-risk patients with pure AI. Valves
are oversized (3), risking annular rupture, to help anchoring. A
Figure 1. Pure Aortic Insufﬁciency and a Transcatheter Solution
Computed tomography multiplanar reconstruction of a pure aortic incompetent valve showing no calciﬁcation of the aortic leaﬂets and a large aortic annulus: coronal
(A), axial (B), and sagittal (C) planes. Transesophageal echocardiographic long- (D) and short- (E) axis images demonstrate severe central aortic valve incompetence.
(F) A self-expandable, cloth-covered, nitinol (nickel titanium) frame (dock) used to retain the transcatheter heart valve (THV) on the native aortic leaﬂets. (G) The dock is
placed deeply in the aortic sinus with no tilting. (H) The apices of the dock (projects as white dots) illustrating encapsulation of all 3 native aortic leaﬂets in the
echocardiographic short-axis image. (I) In the ﬂuoroscopic image, the SAPIEN XT valve (Edwards Lifesciences Corp., Irvine, California) brought transapically is placed
inside the native aortic leaﬂets with the dock placed outside to sandwich the native leaﬂets and anchor the THV. The THV is positioned to align with the aortic side of
the apices of the dock. (J) The THV is placed high on the virtual annulus and anchored by the dock on the native leaﬂets. The transesophageal echocardiographic long-
(K) and short- (L) axis views conﬁrm resolution of aortic insufﬁciency. (M) Computed tomography image shows the aortic side alignment of the THV to the dock apices.
(N) The computed tomography axial view illustrates the circularity of the fully expanded SAPIEN XT valve. See Online Videos 1 and 2. Continued on the next page.
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316worldwide off-label use of the self-expanding CoreValve (Med-
tronic, Minneapolis, Minnesota) had limited success due to difﬁ-
culties with anchoring the valve and highly signiﬁcant residual AI
(4). A recent publication using the second-generation THV (Jena
Valve Technology GmbH, Munich, Germany) via the transapical
approach for an off-label indication for pure AI reported successful
implantation in 5 patients (5).
We illustrate here the use of a dedicated system, the Edwards
Helio-Dock (Edwards Lifesciences, Inc., Irvine, California),
designed to provide a transcatheter solution for pure AI. Through a
series of images, we describe a novel technique to anchor the SA-
PIEN XT (Edwards Lifesciences, Inc.), a balloon-expandable
THV, when the aortic annulus is noncalciﬁed with pure AI. The
current iteration caters for the 29-mm valve, allowing for annular
sizes from 24 to 29 mm with tricuspid or bicuspid aortic valve with
intact leaﬂets.
Figures 1D and 1E demonstrate severe AI due to dilated aortic
root with poor central leaﬂet coaptation. Because the aortic annulus
is noncalciﬁed, the THV is anchored on the native aortic valve
leaﬂets using a superelastic dock made of nitinol and covered with
polyethylene terephthalate fabric to increase friction (Fig. 1F). The 3
prongs on the superior end of the dock are connected to the
attachment arms of the delivery system, which helps to control
placement of the device and ﬁnal release after THV deployment(Figs. 1F and 1G). The dock has an inward radial force creating a
neo-annulus at the leaﬂet level to help anchor the balloon-
expandable heart valve. The dock is positioned from the femoral
artery outside the native aortic leaﬂets, deep in the aortic sinus,
capturing all 3 leaﬂets (Fig. 1G). The dock is exposed by
unsheathing in the ascending aorta, and, using the steerable delivery
system without rapid pacing, it is advanced into position and
checked using transesophageal echocardiography in the short-axis
view to ensure that all 3 aortic leaﬂets are adequately captured
(Fig. 1H, Online Video 1). If not, the dock is pulled back into the
ascending aorta and repositioned until all 3 leaﬂets are captured.
Fluoroscopy ensures that the dock is not angulated and has reached
the bottom of the aortic sinus. The SAPIEN XT valve brought
transapically is positioned centrally, sandwiching the native leaﬂets
between the dock and the THV (Fig. 1I). With rapid pacing, the
THV is deployed (Online Video 2), and post-deployment images
show excellent valve stability with no AI (Figs. 1J to 1L). Post-
deployment computed tomography images (Figs. 1M and 1N)
illustrate the alignment of THV with the dock and the circularity
of the fully expanded SAPIEN XT valve.
As opposed to a self-expanding valve, with no outward forces on
the aortic annulus from the Edwards SAPIEN valve, this system
may prevent further annular expansion, reducing late paravalvular AI
and valve migration. The ﬁrst human case using this novel
Figure 1. Continued
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317technology was at Waikato Hospital, Hamilton, New Zealand, and
the human feasibility study is currently ongoing in surgically high-
risk or inoperable patients with severe AI.
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Surgical Threshold for Bicuspid
Aortic Valve–Associated Aortopathy
Does the Phenotype Matter?
We read with great interest the paper by Hardikar and Marwick (1)
published in a recent issue of iJACC. The authors should be
congratulated for their efforts to address the controversial issue of
bicuspid aortic valve (BAV)–associated aortopathy in their current
meta-analysis. This report is based on a systematic review of the
published literature onBAVaortopathy,with a special focus on aortic-
related events during long-term follow-up. The most important
ﬁnding of thismeta-analysis is the very low risk of adverse aortic events
in patients with BAV disease, which is in contrast to the widespread
perception that exists in the cardiovasculardand in particular the
cardiac surgerydcommunity. Indeed, some have even incorrectly
equated this risk with that observed in patients with connective tissue
disorders (e.g., Marfan syndrome). Hardikar and Marwick (1) were
able to identify BAV patients that were at higher risk of aortic events,
however, according to patients’ age and clinical setting.
The major limitation of the aforementioned meta-analysis is the
heterogeneity of the published literature on BAV-associated aortic
disease. Such heterogeneity was partially addressed by means of
stratiﬁcation by stage of BAV disease (i.e., nonoperated vs. post-
operative BAV patients). However, major heterogeneity also exists
within the post-operative patients, as demonstrated by the highly
signiﬁcant I2 statistic (1). In our experience, this phenomenon may
be explained by the fact that different forms of BAV disease (so-
called BAV phenotypes) are frequently mixed together in published
reports (2). The 2 distinct clinical entities of BAV disease, namely,
BAV in patients presenting with predominant aortic valve stenosis
and dilation of the supra-coronary aorta (i.e., BAV stenosis
phenotype), and BAV in patients presenting with predominant
aortic insufﬁciency and dilation of the proximal aortic root (i.e.,
BAV root phenotype), are characterized by major differences in the
patterns and the prognosis of associated aortopathy (3,4). However,
very few published studies to date have separately analyzed these 2
distinct patient subgroups.
Hardikar and Marwick (1) used the age of BAV patients as an
additional clinical variable to stratify the outcomes of BAV-
associated aortopathy. However, age may also be interpreted as an
indirect marker of the different BAV phenotypes. Evidence of this
can be found in the fact that BAV patients who required aortic root
surgery for aortic regurgitation were in the 5th decade of life,
whereas patients undergoing isolated aortic valve replacement for
BAV stenosis were in their 6th decade. Such ﬁndings are also in linewith previous reports showing that aortic root dilation with resultant
aortic valve insufﬁciency (i.e., root phenotype) is predominantly
found in young, male BAV patients and is associated with a genetic
form of BAV-associated aortopathy (3,4).
The ﬁnding from Hardikar and Marwick (1) that aortic di-
mensions progress more rapidly with increasing age of BAV patients
may be somewhat misleading and should be interpreted with a
caution. The proposed correlation between the rate of aortic
enlargement and increasing age may be explained by the fact that the
2 referenced reports by La Canna et al. (5) and Davies et al. (6)
included patients with dilated BAV aortas only. It is generally
accepted that diameters of already dilated aortas progress more
rapidly; this, rather than just patient age, may account for the
accelerated growth of the proximal aorta observed in these studies.
The annual growth rate of aortic dimensions in distinct clinical
phenotypes (i.e., BAV stenosis vs. root phenotype) would be of great
clinical value and should be a focus of future studies.
With the literature that is currently available, it is very difﬁcult to
accurately deﬁne surgical thresholds for BAV-associated aortopathy,
because most of the published studies consist of mixed BAV
phenotype cohorts and different stages of BAV disease. We strongly
recommend a more homogeneous phenotype-speciﬁc reporting of
outcomes in BAV disease in future studies.
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REPLY : Surgical Threshold for Bicuspid Aortic
Valve–Associated Aortopathy: Does the Phenotype Matter?
We would like to thank Drs. Girdauskas and Borger for their
interest and comments regarding our paper (1). We also concur
regarding the main message of the meta-analysis, which is that
aortopathy associated with bicuspid aortic valve has very low
adverse event ratesdcontrary to the perception that this disease is
